Skip to Content

Trelegy Ellipta Approval History

FDA Approved: Yes (First approved September 18, 2017)
Brand name: Trelegy Ellipta
Generic name: fluticasone furoate, umeclidinium and vilanterol
Dosage form: Inhalation Powder
Company: GlaxoSmithKline
Treatment for: COPD

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Trelegy Ellipta

DateArticle
Apr 24, 2018Approval Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
Sep 18, 2017Approval FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
Nov 21, 2016GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD
Feb  9, 2015GSK and Theravance Announce Start of Phase III Lung Function Study with ‘Closed’ Triple Combination Treatment FF/UMEC/VI for COPD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide